Evidence map›Paper›PMID 23934189›Full record

ArticleOncogene2014

PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.

H Moon, C S Lee, K L Inder, S Sharma, E Choi, D M Black, K-A Lê Cao, C Winterford, J I Coward, M T Ling and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Review
  3. Is Caveolin-1 Required for Retinal Neuroprotection?Advances in experimental medicine and biology · 2025
    Review
  4. Review
  5. Downregulation of Caveolae-Associated Proteins in Psoriasis: A Case Series Study.JID innovations : skin science from molecules to population health · 2024
    Article
  6. Article
  7. Rafting on the Plasma Membrane: Lipid Rafts in Signaling and Disease.Advances in experimental medicine and biology · 2023
    Review
  8. Rafting on the Plasma Membrane: Lipid Rafts in Signaling and Disease.Advances in experimental medicine and biology · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

H MoonThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia.
C S Lee1] Discipline of Pathology, School of Medicine and Molecular Medicine Research Group, University of Western Sydney, Sydney, New South Wales, Australia [2] Department of Anatomical Pathology, Liverpool Hospital, Sydney, New South Wales, Australia.
K L InderThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia.
S Sharma1] Discipline of Pathology, School of Medicine and Molecular Medicine Research Group, University of Western Sydney, Sydney, New South Wales, Australia [2] Department of Anatomical Pathology, Liverpool Hospital, Sydney, New South Wales, Australia.
E Choi1] The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia [2] School of Veterinary Science, The University of Queensland, Brisbane, Queensland, Australia.
D M BlackThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia.
K-A Lê CaoQueensland Facility for Advanced Bioinformatics, The University of Queensland, Brisbane, Queensland, Australia.
C WinterfordSchool of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
J I CowardMater Research, Translational Research Institute, Brisbane, Queensland, Australia.
M T LingAustralian Prostate Cancer Research Centre-Queensland and Institute for Biomedical Health & Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia.
Australian Prostate Cancer BioResource
D J CraikInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
R G PartonInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
P J RussellAustralian Prostate Cancer Research Centre-Queensland and Institute for Biomedical Health & Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia.
M M HillThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia.
The University of Queensland · AUTranslational Research Institute · AULiverpool Hospital · AUQueensland University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caveolin-1 has a complex role in prostate cancer and has been suggested to be a potential biomarker and therapeutic target. As mature caveolin-1 resides in caveolae, invaginated lipid raft domains at the plasma membrane, caveolae have been suggested as a tumor-promoting signaling platform in prostate cancer. However, caveola formation requires both caveolin-1 and cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, non-malignant and malignant prostate tissues. We found that caveolin-1 was induced without the presence of cavin-1 in advanced prostate carcinoma, an expression pattern mirrored in the PC-3 cell line. In contrast, normal prostate epithelia expressed neither caveolin-1 nor cavin-1, while prostate stroma highly expressed both caveolin-1 and cavin-1. Utilizing PC-3 cells as a suitable model for caveolin-1-positive advanced prostate cancer, we found that cavin-1 expression in PC-3 cells inhibits anchorage-independent growth, and reduces in vivo tumor growth and metastasis in an orthotopic prostate cancer xenograft mouse model. The expression of α-smooth muscle actin in stroma along with interleukin-6 (IL-6) in cancer cells was also decreased in tumors of mice bearing PC-3-cavin-1 tumor cells. To determine whether cavin-1 acts by neutralizing caveolin-1, we expressed cavin-1 in caveolin-1-negative prostate cancer LNCaP and 22Rv1 cells. Caveolin-1 but not cavin-1 expression increased anchorage-independent growth in LNCaP and 22Rv1 cells. Cavin-1 co-expression reversed caveolin-1 effects in caveolin-1-positive LNCaP cells. Taken together, these results suggest that caveolin-1 in advanced prostate cancer is present outside of caveolae, because of the lack of cavin-1 expression. Cavin-1 expression attenuates the effects of non-caveolar caveolin-1 microdomains partly via reduced IL-6 microenvironmental function. With circulating caveolin-1 as a potential biomarker for advanced prostate cancer, identification of the molecular pathways affected by cavin-1 could provide novel therapeutic targets.

Indexed as

ActinsAgedAnimalsCaveolin 1Cell Line, TumorCell ProliferationCell Transformation, NeoplasticDisease ProgressionGene Expression Regulation, NeoplasticHumansInterleukin-6MaleMembrane MicrodomainsMiceMiddle AgedNeoplasm MetastasisACTA2 protein, humanActinsCaveolin 1CAVIN1 protein, humanInterleukin-6Proto-Oncogene Proteins c-aktReceptors, AndrogenRNA-Binding Proteins

Identifiers

PMID23934189
OpenAlexW2044446034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.